drugset / Trial / NCT00071981
Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma
Phase 2
Completed
175 enrolled
Eastern Cooperative Oncology Group
National Cancer Institute (NCI) · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
RATIONALE: Vaccines made from peptides may make the body build an immune response to kill tumor cells. PURPOSE: This randomized phase II trial is studying four different vaccines using melanoma peptides from cytotoxic T cells and helper T cells to see how well they work in treating patients with metastatic melanoma.
Timeline
- Start
- 2005-05-09
- Primary completion
- 2011-08
- Completion
- 2014-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | melanoma helper peptide vaccine | Vaccine | — | Subcutaneous |
| Subject | multi-epitope melanoma peptide vaccine | Vaccine | — | — |
| Subject | tetanus peptide melanoma vaccine | Peptide | — | Subcutaneous |
| Background | incomplete Freund's adjuvant | Other / unclassified | — | Subcutaneous |
| Background | sargramostim | Protein / enzyme biologic | — | — |